Publications
Detailed Information
Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wu, Huali | - |
dc.contributor.author | Ramanathan, Ramesh K. | - |
dc.contributor.author | Zamboni, Beth A. | - |
dc.contributor.author | Strychor, Sandra | - |
dc.contributor.author | Ramalingam, Suresh | - |
dc.contributor.author | Edwards, Robert P. | - |
dc.contributor.author | Friedland, David M. | - |
dc.contributor.author | Stoller, Ronald G. | - |
dc.contributor.author | Belani, Chandra P. | - |
dc.contributor.author | Maruca, Lauren J. | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Zamboni, William C. | - |
dc.date.accessioned | 2021-01-31T11:57:06Z | - |
dc.date.available | 2021-01-31T11:57:06Z | - |
dc.date.created | 2020-08-24 | - |
dc.date.issued | 2012-02 | - |
dc.identifier.citation | Journal of Clinical Pharmacology, Vol.52 No.2, pp.180-194 | - |
dc.identifier.issn | 0091-2700 | - |
dc.identifier.other | 111384 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173155 | - |
dc.description.abstract | S-CKD602 is a pegylated long-circulating liposomal formulation of CKD-602, a potent topoisomerase I inhibitor. A population pharmacokinetic (PK) model for encapsulated and released CKD-602 following administration of S-CKD602 was developed to assess factors that may influence S-CKD602 PK. Plasma samples from 45 patients with solid tumors were collected in a phase 1 study. S-CKD602 was administered as a 1-hour intravenous infusion with doses ranging from 0.1 to 2.5 mg/m(2). Plasma concentrations of encapsulated and released CKD-602 were used to develop a population PK model using NONMEM. PK of encapsulated CKD-602 was described by a 1-compartment model with nonlinear clearance, and PK of released CKD-602 was described by a 2-compartment model with linear clearance for all patients. Covariate analysis revealed that tumor in the liver was a significant covariate for clearance of encapsulated CKD-602 and that age significantly influenced the release rate of CKD-602 from S-CKD602. Maximum elimination rate in patients with liver tumor is 1.5-fold higher compared with patients without liver tumor. Release rate of CKD-602 from S-CKD602 in patients less than 60 years old was 2.7-fold higher compared with patients 60 years old or older. These observations have potential implications in the optimal dosing of liposomal agents. | - |
dc.language | 영어 | - |
dc.publisher | SAGE Publications | - |
dc.title | Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1177/0091270010394851 | - |
dc.citation.journaltitle | Journal of Clinical Pharmacology | - |
dc.identifier.wosid | 000299657600004 | - |
dc.identifier.scopusid | 2-s2.0-84863071445 | - |
dc.citation.endpage | 194 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 180 | - |
dc.citation.volume | 52 | - |
dc.identifier.sci | 000299657600004 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | PHASE-I | - |
dc.subject.keywordPlus | THERAPEUTIC-EFFICACY | - |
dc.subject.keywordPlus | ANTICANCER AGENTS | - |
dc.subject.keywordPlus | LIVER METASTASES | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | INFUSION | - |
dc.subject.keywordPlus | TUMOR | - |
dc.subject.keywordPlus | XENOGRAFTS | - |
dc.subject.keywordPlus | PACLITAXEL | - |
dc.subject.keywordAuthor | S-CKD602 | - |
dc.subject.keywordAuthor | population pharmacokinetics | - |
dc.subject.keywordAuthor | pegylated liposome | - |
dc.subject.keywordAuthor | nonlinear kinetics | - |
dc.subject.keywordAuthor | liver metastasis | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.